New Supplement Timelines, Categories Proposed For BsUFA III
Executive Summary
The ideas could potentially address sponsor concerns about the effects of slow reviews.
You may also be interested in...
US Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement
Talks are completed, leaving only the generic drug user fee reauthorization negotiations ongoing.
BsUFA III Negotiations Nearly Done; Commitment Letter Being Written
Supplement approval timeline and regulatory science issues apparently have been resolved.
‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively
ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.